Albert Bourla

Born in Thessaloniki, Greece in 1961 to a family of Sephardic Jewish descent that survived the Holocaust, Bourla is a veterinarian by training who joined Pfizer in 1993 and rose through the company's animal health and vaccine divisions. Bourla's defining achievement was the development and deployment of the COVID-19 vaccine in partnership with BioNTech. The decision to pursue mRNA technology, bypass government funding through Operation Warp Speed to maintain independence, and commit to delivering a vaccine in under a year was an extraordinary bet that paid off. Pfizer-BioNTech's Comirnaty became the world's most widely used COVID vaccine, generating over $37 billion in revenue in 2022 alone. The post-pandemic period has been far more challenging. As COVID vaccine and Paxlovid antiviral demand collapsed, Pfizer's revenue fell from $100 billion in 2022 to under $60 billion, one of the sharpest revenue declines in pharmaceutical history. The stock fell over 50% from its highs, and Bourla faced intense investor scrutiny. His response was the $43 billion acquisition of Seagen, a leading antibody-drug conjugate (ADC) company with breakthrough cancer treatments. This transformative deal aims to make oncology Pfizer's growth engine for the next decade. Bourla has also launched a $4 billion cost-cutting program and is working to demonstrate that the company's base business — including blockbusters in blood thinners, heart failure, and migraine — can stabilize revenue even without pandemic-era demand.